Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 12/20 | 0.42 |
| ▸ | CDK2 | P24941 | 11/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 8/20 | 0.40 |
| ▸ | CSNK1E | P49674 | 8/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30013789 | 1.00 | CDK9 (0.42) | CDK9CDK2CSNK1DCSNK1ECCNE1 | |
| SCHEMBL23497822 | 0.91 | CDK2 (0.40) | CDK9CDK2CSNK1DCSNK1E | |
| SCHEMBL30013666 | 0.91 | CDK2 (0.40) | CDK9CDK2CSNK1DCSNK1E | |
| SCHEMBL30013054 | 0.81 | CDK2 (0.39) | CDK9CDK2CCNE1 | |
| SCHEMBL23508048 | 0.81 | CDK2 (0.39) | CDK9CDK2CCNE1 | |
| SCHEMBL23508209 | 0.80 | CDK2 (0.38) | CDK9CDK2CCNE1 | |
| SCHEMBL30012848 | 0.80 | CSNK1D (0.52) | CDK9CDK2CSNK1DCSNK1ECCNE1 | |
| SCHEMBL23497873 | 0.80 | CSNK1D (0.52) | CDK9CDK2CSNK1DCSNK1ECCNE1 | |
| SCHEMBL23508287 | 0.79 | CDK2 (0.49) | CDK9CDK2CSNK1DCSNK1ECCNE1 | |
| SCHEMBL23508266 | 0.79 | CSNK1E (0.40) | CDK9CSNK1DCSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117034-A1 | PYRAZOLOTRIAZINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-20 | — | — | US | disclosed |
| WO-2021116178-A1 | PYRAZOLOTRIAZINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117034-A1 | PYRAZOLOTRIAZINES | BRCA1, TPX2, CCND2 | CDK9 889/4885CDK2 43/4885CSNK1D 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.